公开(公告)号：US20240150462A1

公开(公告)日：2024-05-09

申请号：US18549897

申请日：2022-03-11

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： Richard BROKX ,  Jacqueline M. MASON ,  Mark Robert BRAY ,  Gordon S. DUNCAN

IPC: C07K16/28 ,  A61K45/06 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/52 ,  C07K2317/565

Abstract: The invention provides novel anti-LILR antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer, autoimmune disease, or allergic inflammation.

公开(公告)号：US20240141025A1

公开(公告)日：2024-05-02

申请号：US18414178

申请日：2024-01-16

Applicant: NOVO NORDISK A/S ,  University Health Network

Inventor： YUE LIU ,  TARLOCHAN S. NIJJAR ,  AVIJIT CHAKRABARTTY ,  JEFFREY N. HIGAKI

IPC: C07K16/18 ,  A61K51/10

CPC classification number: C07K16/18 ,  A61K51/1018 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/92

Abstract: The invention provides antibodies that specifically bind transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.

公开(公告)号：US20240138698A1

公开(公告)日：2024-05-02

申请号：US17974867

申请日：2022-10-27

Applicant: GE Precision Healthcare LLC ,  University Health Network

Inventor： Afis Ajala ,  Jianwei Qiu ,  John Karigiannis ,  Radhika Madhavan ,  Desmond Teck Beng Yeo ,  Thomas Kwok-Fah Foo ,  Andres M. Lozano ,  Alexandre Boutet ,  Jurgen Germann

IPC: A61B5/055 ,  G06T7/00

CPC classification number: A61B5/055 ,  G06T7/0012 ,  G06T2207/10088

Abstract: A system for optimizing DBS parameters for a subject includes automatically performing actions via a processor. The actions include obtaining functional MRI data of a brain of the subject acquired utilizing an MRI system during DBS of the brain utilizing a first set of DBS parameters. The actions include generating functional MRI response maps from the functional MRI data. The actions include extracting, utilizing an unsupervised autoencoder-based neural network, features from the functional MRI response maps. The actions include determining, utilizing a deep learning-based DBS parameter classification model, whether the first set of DBS parameters are optimal DBS parameters for the subject based on the features. The actions include, when the first set of DBS parameters are not the optimal DBS parameters, predicting, utilizing a deep learning-based DBS parameter prediction model, a second set of DBS parameters that are the optimal DBS parameters for the subject based on the features.

公开(公告)号：US11925649B2

公开(公告)日：2024-03-12

申请号：US16160403

申请日：2018-10-15

Applicant: University of Manitoba ,  University Health Network ,  THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor： Paul Fernyhough ,  Nigel A. Calcutt ,  Lakshmi Kotra

IPC: A61K31/5513 ,  A61K31/46 ,  A61K31/496 ,  A61K31/5517 ,  C07D417/12

CPC classification number: A61K31/5513 ,  A61K31/46 ,  A61K31/496 ,  A61K31/5517 ,  C07D417/12

Abstract: Treatments for therapy of a diabetic symmetrical polyneuropathy a subject in need thereof. The treatments includes administration of compositions comprising: an effective amount of a muscarinic acetylcholine receptor antagonist exemplified by pirenzepine, telenzepine, atropine, or derivatives thereof or salts thereof or analogs thereof or derivatives thereof, and a pharmacologically acceptable carrier. The composition may be injectable or alternatively, may be applied topically or alternatively, may be delivered orally. A suitable topical composition may comprise a lotion, a cream, a gel, or a viscous fluid. The muscarinic acetylcholine receptor antagonist may be a muscarinic acetylcholine receptor antagonist salt or a muscarinic acetylcholine receptor antagonist derivative or a muscarinic acetylcholine receptor antagonist analog.

公开(公告)号：US11925467B2

公开(公告)日：2024-03-12

申请号：US17052247

申请日：2019-04-30

Applicant: University Health Network

Inventor： Vijay Singh Chauhan ,  Adrian Michael Suszko

IPC: A61B5/30 ,  A61B5/00 ,  A61B5/35 ,  A61B5/352 ,  A61N1/362

CPC classification number: A61B5/352 ,  A61B5/30 ,  A61B5/35 ,  A61B5/4836 ,  A61B5/4848 ,  A61N1/362 ,  A61B2562/222

Abstract: Various embodiments are described herein for a system and a method for assessing a risk of ventricular arrhythmias for a patient. For example, the method may comprise receiving ECG data obtained from the patient; analyzing the ECG data to detect abnormal QRS peaks; determining the risk of ventricular arrhythmias for the patient based on the detected abnormal QRS peaks; and providing an indication of the risk of ventricular arrhythmias for the patient. The system may be configured to perform this method.

公开(公告)号：US11920196B2

公开(公告)日：2024-03-05

申请号：US17337163

申请日：2021-06-02

Applicant: University Health Network

Inventor： Mohit Kapoor ,  Rajiv Gandhi ,  Shabana Amanda Ali

IPC: C12Q1/6876

CPC classification number: C12Q1/6876 ,  C12Q2600/178

Abstract: A method comprising obtaining a substantially cell-free sample of blood plasma or blood serum from a subject with osteoarthritis; and detecting a presence of or measuring a level of novel_miRNA_1 (gucuggcucaggguuggg) (SEQ ID NO: 1), novel_miRNA_2 (ucccuguucgggcgccacu) (SEQ ID NO: 2), novel_miRNA_3 (uguuuagcauccuguagccugc) (SEQ ID NO: 3), and novel_miRNA_4 (uaguggguuaucagaacu) (SEQ ID NO: 4). Also provided are methods where additional miRNAs are detected including novel miRNA 5 (SEQ ID NO: 5), novel miRNA 6 (SEQ ID NO: 6), novel miRNA 7 (SEQ ID NO: 7), novel miRNA 8 (SEQ ID NO: 8), novel miRNA 9 (SEQ ID NO: 9), novel miRNA 10 (SEQ ID NO: 10), novel miRNA 11 (SEQ ID NO: 11), novel miRNA 12 (SEQ ID NO: 12), novel miRNA 13 (SEQ ID NO: 13), hsa-miR-335-3p, hsa-miR-199a-5p, hsa-miR-671-3p, hsa-miR-1260b, hsa-miR-191-3p, hsa-miR-335-5p and/or hsa-miR-543.

公开(公告)号：US11908568B2

公开(公告)日：2024-02-20

申请号：US17077413

申请日：2020-10-22

Applicant: CANON MEDICAL SYSTEMS CORPORATION ,  University Health Network

Inventor： Ting Xia ,  Zhou Yu ,  Patrik Rogalla ,  Bernice Hoppel

IPC: G06T7/00 ,  G16H30/20 ,  G06N3/04 ,  G16H50/30 ,  G16H50/20

CPC classification number: G16H30/20 ,  G06N3/04 ,  G06T7/0014 ,  G16H50/20 ,  G16H50/30 ,  G06T2207/10028 ,  G06T2207/10081 ,  G06T2207/30168

Abstract: The present disclosure relates to a method for patient-specific optimization of imaging protocols. According to an embodiment, the present disclosure relates to a method for generating a patient-specific imaging protocol, comprising acquiring scout scan data, the scout scan data including scout scan information and scout scan parameters, generating a simulated image based on the acquired scout scan data, deriving a simulated dose map from the generated simulated image, determining image quality of the generated simulated image by applying machine learning to the generated simulated image, the neural network being trained to generate at least one probabilistic quality representation corresponding to at least one region of the generated simulated image, evaluating the determined image quality relative to a image quality threshold and the derived simulated dose map relative to a dosage threshold, optimizing. based on the evaluating, scan acquisition parameters and image reconstruction parameters, and generating, optimal imaging protocol parameters, wherein the optimal imaging protocol parameters maximize image quality while minimizing radiation exposure.

公开(公告)号：US11857317B2

公开(公告)日：2024-01-02

申请号：US17961480

申请日：2022-10-06

Applicant: The Trustees of Dartmouth College

Inventor： Pablo Valdes ,  Frederic Leblond ,  Keith D. Paulsen ,  Brian Campbell Wilson ,  David W. Roberts ,  Michael Jermyn

IPC: A61B5/1455 ,  A61B5/1459 ,  A61B1/04 ,  A61B5/145 ,  A61B5/00 ,  A61B5/1495 ,  A61B1/06 ,  A61B5/055 ,  G01J3/28 ,  A61B1/05 ,  G01J3/12 ,  G01J3/02 ,  A61B1/00 ,  A61B1/07 ,  A61B1/313

CPC classification number: A61B5/14556 ,  A61B1/00009 ,  A61B1/000094 ,  A61B1/00165 ,  A61B1/00193 ,  A61B1/00194 ,  A61B1/042 ,  A61B1/043 ,  A61B1/05 ,  A61B1/0646 ,  A61B1/0669 ,  A61B1/0684 ,  A61B1/07 ,  A61B5/0071 ,  A61B5/0077 ,  A61B5/055 ,  A61B5/1459 ,  A61B5/1495 ,  A61B5/14546 ,  A61B5/14553 ,  A61B5/7264 ,  G01J3/0229 ,  G01J3/1256 ,  G01J3/2823 ,  A61B1/3132 ,  G01J2003/1269 ,  G01J2003/2826

Abstract: An imaging system, such as a surgical microscope, laparoscope, or endoscope or integrated with these devices, includes an illuminator providing patterned white light and/or fluorescent stimulus light. The system receives and images light hyperspectrally, in embodiments using a hyperspectral imaging array, and/or using narrowband tunable filters for passing filtered received light to an imager. Embodiments may construct a 3-D surface model from stereo images, and will estimate optical properties of the target using images taken in patterned light or using other approximations obtained from white light exposures. Hyperspectral images taken under stimulus light are displayed as fluorescent images, and corrected for optical properties of tissue to provide quantitative maps of fluorophore concentration. Spectral information from hyperspectral images is processed to provide depth of fluorophore below the tissue surface. Quantitative images of fluorescence at depth are also prepared. The images are displayed to a surgeon for use in surgery.

公开(公告)号：US20230330152A1

公开(公告)日：2023-10-19

申请号：US18336410

申请日：2023-06-16

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： Gordon KELLER ,  April M. CRAFT

IPC: A61K35/32 ,  C12N5/077 ,  G01N33/50

CPC classification number: A61K35/32 ,  C12N5/0655 ,  G01N33/5044 ,  C12N2501/115 ,  C12N2501/155 ,  C12N2501/16 ,  C12N2501/415 ,  C12N2501/999 ,  C12N2503/02 ,  C12N2506/02 ,  C12N2506/03

Abstract: A method for generating chondrocytes and/or cartilage, optionally articular like non-hypertrophic chondrocyte cells and/or cartilage like tissue and/or hypertrophic chondrocyte like cells and/or cartilage like tissue, the method comprising:

a. culturing a primitive streak-like mesoderm population, optionally a CD56+, PDGFRalpha+ KDR- primitive streak-like mesoderm population, with a paraxial mesoderm specifying cocktail comprising:

i. a FGF agonist;
ii. a BMP inhibitor; optionally Noggin, LDN-193189, Dorsomorphin; and
iii. optionally one or more of a TGFbeta inhibitor, optionally SB431524; and a Wnt inhibitor, optionally DKK1, IWP2, or XAV939;

to specify a paraxial mesoderm population expressing cell surface CD73, CD105 and/or PDGFR-beta;
b. generating a chondrocyte precursor population comprising:

i. culturing the paraxial mesoderm population expressing CD73, CD105 and/or PDGFR-beta at a high cell density optionally in serum free or serum containing media;
ii. culturing the high cell density CD73+, CD105+ and/or PDGFRbeta+ paraxial mesoderm population with a TGFbeta3 agonist in serum free media to produce a high cell density Sox9+, collagen 2+ chondrocyte precursor population; and


c. either

i. culturing the high cell density Sox9+, collagen 2+ chondrocyte precursor population with the TGFbeta3 agonist for an extended period of time to produce an articular like non-hypertrophic chondrocyte cells and/or cartilage like tissue; or
ii. culturing the high cell density Sox9+ collagen2+ chondrocyte precursor population with a BMP4 agonist for an extended period of time to produce a hypertrophic chondrocyte like cells and/or cartilage like tissue.

公开(公告)号：US20230302096A1

公开(公告)日：2023-09-28

申请号：US18047129

申请日：2022-10-17

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： Philippe P. MONNIER ,  Nardos G. TASSEW

IPC: A61K38/44 ,  A61K31/137 ,  C07K16/28 ,  A61K31/724 ,  A61K31/365 ,  A61K31/7048 ,  A61K38/48 ,  C07K14/435 ,  C07K14/705 ,  G01N33/53 ,  A61K31/495 ,  A61K38/17 ,  G01N33/50

CPC classification number: A61K38/443 ,  A61K31/137 ,  C07K16/28 ,  C12Y101/03006 ,  A61K31/724 ,  A61K31/365 ,  A61K31/7048 ,  A61K38/482 ,  C07K14/435 ,  C07K14/705 ,  G01N33/53 ,  A61K31/495 ,  A61K38/177 ,  G01N33/5058 ,  A61K2039/505

Abstract: Disclosed herein is an agent that modulates a cis interaction between Repulsive Guidance Molecule A (RGMa) and Neogenin or lipid rafts. Modulation by the agent may include blocking the cis interaction between RGMa and Neogenin and/or disrupting lipid rafts. In turn, this promotes neuronal cell survival and axon growth and/or regeneration. Also disclosed herein is a method of treating a disease in a subject in need thereof. The method may include administering the agent to the subject. Further disclosed herein is a method of identifying an agent that modulates the cis interaction between RGMa and Neogenin.